{
    "name": "vibegron",
    "comment": "Rx",
    "other_names": [
        "Gemtesa"
    ],
    "classes": [
        "Beta3 Agonists"
    ],
    "source": "https://reference.medscape.com/drug/gemtesa-vibegron-4000077",
    "pregnancy": {
        "common": [
            "No data available on use in pregnant females to evaluate for drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Delayed fetal skeletal ossification was observed in rabbits at ~898-fold clinical exposure, in presence of maternal toxicity",
                    "Developmental toxicity was observed in offspring at ~458-fold clinical exposure, in the presence of maternal toxicity",
                    "No effects on offspring at 89-fold clinical exposure"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data available on presence in human milk, effects on breastfed infants, or effects on milk production",
            "When a single oral dose of radiolabeled vibegron was administered to postnatal nursing rats, radioactivity was observed in milk",
            "If drug is present in animal milk, it is likely that drug will be present in human milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Urinary retention",
                    "description": [
                        "Urinary retention reported",
                        "Risk increased in patients with bladder outlet obstruction and patients taking muscarinic antagonists medications; closely monitor patients during treatment",
                        "Monitor for signs and symptoms of urinary retention",
                        "Discontinue in patients who develop urinary retention"
                    ]
                },
                {
                    "type": "Drug interaction overview ",
                    "description": [
                        "Digoxin",
                        "Vibegron increases digoxin maximal concentrations and systemic exposure ",
                        "Monitor serum digoxin concentrations before initiating, during therapy, and for dose titration",
                        "Continue monitoring digoxin concentrations after discontinuing vibegron and adjust digoxin dose as needed"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Urinary tract infection",
            "percent": "6.6"
        },
        {
            "name": "Headache",
            "percent": "4"
        },
        {
            "name": "Bronchitis",
            "percent": "2.9"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "2.8"
        },
        {
            "name": "Diarrhea",
            "percent": "2.2"
        },
        {
            "name": "Nausea",
            "percent": "2.2"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "2"
        },
        {
            "name": "Dry mouth",
            "percent": "2"
        },
        {
            "name": "Constipation",
            "percent": "2"
        },
        {
            "name": "Residual urine volume increased",
            "percent": "2"
        },
        {
            "name": "Urinary retention",
            "percent": "2"
        },
        {
            "name": "Hot flush",
            "percent": "2"
        }
    ]
}